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Background: Multiple therapeutic strategies to restore immune regulation and slow type 1 
diabetes (T1D) progression are in development and testing. A major challenge has been defining 
biomarkers to prospectively identify subjects likely to benefit from immunotherapy and/or 
measure intervention effects. We previously found that compared to healthy controls, Tregs from 
children with new-onset T1D have an altered Treg gene signature (TGS), suggesting this could 
be an immunoregulatory biomarker.  
Methods: nanoString was used to assess the TGS in sorted Tregs (CD4+CD25hiCD127lo) or 
Peripheral Blood Mononuclear Cells (PBMC) from individuals with T1D or type 2 diabetes, 
healthy controls, or T1D recipients of immunotherapy. Biomarker discovery pipelines were 
developed and applied to various sample group comparisons.  
Results: Compared to controls, the TGS in isolated Tregs or PBMCs is altered in adult new-onset 
and cross-sectional T1D cohorts, with sensitivity and specificity of biomarkers increased by 
including T1D-associated single nucleotide polymorphisms in algorithms. The TGS was distinct 
in T1D versus type 2 diabetes, indicating disease-specific alterations. TGS measurement at the 
time of T1D onset revealed an algorithm that accurately predicted future rapid versus slow C-
peptide decline, as determined by longitudinal analysis of placebo arms of START and T1DAL 
trials. The same algorithm stratified participants in a phase I/II clinical trial of ustekinumab (aIL-
12/23p40) for future rapid versus slow C-peptide decline.  
Conclusion: These data suggest that biomarkers based on measuring Treg gene signatures could 





Insufficient FOXP3+ regulatory T cell (Treg) control of T cell-mediated destruction of beta-cells 
likely contributes to type 1 diabetes (T1D) (1). Monogenic mutations in FOXP3 resulting in a 
lack of functional Tregs lead to T1D (2) and several T1D risk alleles occur in Treg-associated 
genes (e.g. single nucleotide polymorphisms [SNPs] in CD25, PTPN2 and PTPN22) (1). 
Accordingly, multiple studies are testing whether immunotherapy-based methods to boost Treg 
function can prevent or delay T1D progression (1, 3, 4). For example, inflammatory cytokine 
blockade (e.g. ustekinumab, aIL-12/23p40 (5)), co-stimulation targeting (e.g. alefacept, LFA3-4-
Ig (6)), or Treg expansion (e.g. low-dose IL-2; cellular therapy (7, 8)) aim to restore the 
immunoregulatory balance. However, availability of clinically-applicable tests to measure 
changes in immunity during such trials is limited (3), with an on-going search for biomarkers to 
stratify patients likely to respond to a given therapy and track changes in immune regulation (4, 
9).  
 We previously developed a composite biomarker assay which measures expression of 37 
genes and discriminates between Tregs and conventional T cells (Tconvs) regardless of 
activation state and showed that Tregs from pediatric new onset T1D patients have a 
significantly altered gene signature (10). Here we tested whether Treg gene signatures (TGS) 
could also identify Treg alterations in adults with T1D and investigated the predictive power of 





Adults with T1D have an altered Treg gene signature in sorted Tregs and PBMCs 
We previously found that pediatric new onset T1D Tregs had a significantly different TGS 
compared to healthy children (10) and first tested if this was also true in adults. Tregs 
(CD4+CD25hiCD127lo) were isolated from young adults with new onset T1D (18-35 years of 
age, <100 days after diagnosis, n=20, Figure 1A), a cross-sectional T1D cohort ((9), n=40, 
Figure 1B), or age- and sex-matched healthy controls (HC, n=10 or n=37). Expression of the 
TGS was measured using a nCounter FLEX and biomarker discovery analysis applied. We found 
the TGS distinguished between T1D and healthy Tregs with high AUCs [area under the 
receiving operating characteristic curves] in both cohorts (Figure 1A&B, AUC=0.830, =0.953). 
Cut-offs for sensitivity (true positives) and specificity (true negatives) determination were set 
between 0.25 and 0.75, revealing high sensitivity and specificity for both cohorts. 
 Genetic risk alleles including SNPs in CD25, PTPN2 and PTPN22 are associated with 
CD25 expression, response to IL-2, FOXP3 stability, and Treg function in T1D (1). We thus 
hypothesized that genotype information might refine biomarker accuracy. Biomarker discovery 
using the cross-sectional T1D cohort and including genotype(s) revealed that while overall 
AUCs were similar to those obtained without genotype, there was slightly improved sensitivity 
in several cases (Figure 2). For example, adding CD25 rs2104286 number of disease variants 
[NDV] improved the sensitivity from 0.875 (Figure 1B) to 0.950 (Figure 2C), but overall 




 Clinical application of biomarker tests should ideally entail minimal sample processing to 
simplify implementation, reduce processing errors, and increase reproducibility. We therefore 
next examined whether differential TGS expression could be detected in unfractionated PBMCs. 
Gene expression in PBMC lysates from adult new onset (n=19, Figure 3A) and cross-sectional 
(n=35, Figure 3B) T1D cohorts, and age- and sex-matched controls (HC, n=10 or n=38) were 
measured and biomarker discovery analysis applied. Surprisingly, gene expression in PBMC 
lysates also revealed highly sensitive and specific algorithms that discriminated between healthy 
controls and new onset or cross-sectional T1D cohorts (AUC= 0.895, =0.977, respectively). 
Adding genotype information to biomarker discovery generated near perfect classification of 
T1D versus HCs with most AUCs, sensitivity and specificity >0.900 (Figure 4). Thus, the 
inclusion of Treg-associated SNPs is valuable when assessing changes in the overall 
immunoregulatory balance by measuring the TGS in PBMC lysates.  
 
Differences in gene usage between Treg and PBMC-derived algorithms 
The varying number and identity of genes in each best-performing algorithm led us to compare 
gene usage across algorithms derived from Tregs versus PBMCs in the cross-sectional T1D 
cohort (Figure 5). We found that there were 10 core genes in all of the best performing 
algorithms derived from sorted Tregs (Figure 5A). These included genes associated with DNA 
accessibility (METTL7A, a methyltransferase), transcription (ZNF532, VAV3, RBMS3), 
translation (RPL23A, a ribosomal protein), signal transduction (VAV3, TCR mediated signalling 
(11)), and cytokine receptors (CSF2RB, IL1R1, IL7R).  
Examination of the PBMC-based algorithm also revealed 10 core genes (Figure 5B), with 
notable similarities and differences to the Treg-derived algorithms. For example, FOXP3 
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(significantly lower expression in PBMC T1D versus controls, p=0.0034, data not shown) and 
TRIB1 (significantly higher expression in PBMC T1D versus controls, p<0.0001, data not 
shown) were included in all PBMC-based algorithms, but not in any derived from sorted Tregs. 
In contrast, IL1RN and RPL23A were always present in both Treg- and PBMC-based algorithms. 
Hence, PBMC-based algorithms may detect changes in Treg to Tconv ratios which are 
eliminated when analysing TGS of sorted Tregs. 
 
Treg gene signature algorithms in type 1 versus type 2 diabetes 
TGS changes could be related to poor glucose homeostasis rather than a change in immune 
regulation. We thus measured the TGS in sorted Tregs or PBMCs from type 2 diabetes (T2D) 
patients, and re-ran the age- and sex-matched T1D and HC lysates in parallel, in this case using 
the nCounter SPRINT system. Principle Components Analysis (PCA) was performed separately 
on Treg and PBMC data to highlight differences between patients (i.e. HC vs T1D vs T2D) 
rather than reiterate differences present between sample types (i.e. Tregs vs PBMCs). Analysis of 
the unweighted TGS revealed distinct clustering of T2D, T1D and HCs for both Treg and PBMC 
samples (Figure 6).  
 For these experiments, since we re-ran T1D and HC cohort samples from Figures 1&3 
with the T2D samples on the nCounter SPRINT system we also had to opportunity to test T1D 
versus HC algorithms from Figure 1B “off-the-shelf”, finding excellent replication of the AUC 
(=1.000) and, without changing cut-offs, perfect sensitivity (=1.000) but low specificity (=0.222, 
Figure 7A). New biomarker analysis comparing T1D to T2D, or T2D to HC using Treg lysates 
also revealed algorithms that were highly sensitive and specific (AUCs >0.9, Figure 7B&C). 
Similar results were obtained when PBMC lysates were analysed. "Off-the-shelf" application of 
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the algorithm from Figure 3B revealed a high AUC (=0.922) and sensitivity (=0.900), but low 
specificity (=0.444, Figure 7D). As with sorted Tregs, new biomarker discovery in PBMCs also 
revealed distinct gene expression in T1D versus T2D, and between T2D and healthy controls 
(Figure 7 E&F). Each cohort comparison was defined by distinct sets of genes (Figure 7G&H), 
indicating there are intrinsic and extrinsic differences in Treg biology in T1D, T2D and HCs. 
 
Application of the Treg gene signature as clinical trial monitoring tool. 
A limitation of T1D disease management and clinical trials is the lack of non-invasive 
biomarkers to predict C-peptide trajectory and measure intervention benefit (9). Hence, we asked 
whether the TGS might predict disease trajectory. Together with the JDRF Biomarker Working 
Group and the Immune Tolerance Network, we obtained longitudinal samples from the placebo 
arms of the T1DAL and START trials (9). Subjects were divided into tertiles with slow, 
moderate or rapid C-peptide decline, as determined by mixed meal tolerance tests (MMTTs), 
according to absolute change in C-peptide levels from baseline (<100 days after diagnosis) to 24 
months later (Figure 8A)  
 We measured the TGS in Treg and PBMC lysates from month 0 samples and performed 
biomarker discovery, seeking an algorithm that could predict future rapid versus slow C-peptide 
decline. Although the sample size was small (n=7 rapid vs 9 slow decline), the TGS in Treg 
lysates predicted C-peptide decline with an AUC=0.730 (Figure 8B). Subjects with a moderate 
rate of C-peptide decline showed an intermediate biomarker score. Furthermore, plotting 
normalized gene expression of month 0 Treg lysates showed trends in line with C-peptide 
decline (Figure 8C). Specifically, expression of all 4 genes incorporated in the algorithm either 
increased (C8ORF70, PMSL11, STAM) or decreased (ICA1) with progressively worse future C-
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peptide decline. Expression of 2 additional genes not incorporated in the algorithm, ID2 and 
ZBTB38 also showed trends in line with C-peptide decline. In contrast, biomarker analysis of 
PBMC lysates was ineffective at discriminating between these groups (data not shown), 
suggesting that Treg-intrinsic alterations rather than an overall change in immunoregulatory 
balance may be better able to predict future disease course.   
 Finally, we tested if the TGS could predict C-peptide decline in the setting of 
immunotherapy. Specifically, we used samples from a phase I/II safety trial of ustekinumab 
(aIL-12/23 p40) in adult new onset T1D (NCT02117765). Ustekinumab is commonly used in 
psoriasis and inflammatory bowel disease (12), and its ability to block IL-12 and IL-23 might 
restore the abnormal balance of T helper subsets, and/or IL-17-producing Tregs that we (13) and 
others (14, 15) previously described in T1D. C-peptide was measured by MMTTs pre-treatment 
(month 0), and at 1 and 12 months after ustekinumab treatment. Subjects were divided into slow 
(n=11) or rapid (n=5) C-peptide decline based on reported expected rates of decline (16) (Figure 
9A). We first applied the unmodified algorithm from Figure 8B "off-the-shelf" to pre-treatment 
Treg gene expression data finding this algorithm prospectively identified rapid versus slow C-
peptide decline with AUC=0.709; however, the specificity was low (=0.182, Figure 9B), 
indicating that cut-offs for sensitivity/specificity calculations need refinement.  
 We then asked whether the TGS changed over the course of ustekinumab therapy by 
dividing month 9 Treg gene expression data by pre-treatment (month 0) data. Biomarker 
discovery revealed excellent predictive models (AUC=0.818, sensitivity=0.909 and 
specificity=0.800) that identified subjects with slow versus rapid C-peptide decline (Figure 9C). 
Evidence that the algorithm improved when both pre-treatment and month 9 data were included 
suggests that subjects with sustained versus rapidly declining C-peptide may have differing 
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ustekinumab-driven changes in their TGS. As with the non-interventional longitudinal samples, 
algorithms based on month 0 PBMC lysates were ineffective (data not shown).   
 Finally, the TGS at month 9 could also differentiate between slow and rapid C-peptide 
decline (Figure 9D&E). Interestingly, at this time point both Treg and PBMC-derived signatures 
yielded good algorithms (AUCs=0.900 and =0.745, respectively, Figure 9D&E). These data 
suggest that the TGS may detect ustekinumab-mediated changes in Treg-intrinsic gene 
expression and in the balance between Tregs and Tconvs upon immunotherapy. We found some 
gene usage overlap with algorithms described in previous Figures (Figure 9F).  
 
Discussion 
Here we build on our previous finding that Tregs from children with new-onset T1D have an 
altered TGS and show that this is also true in adult new-onset and cross-sectional T1D cohorts. 
The altered T1D TGS did not appear to be determined to changes in glucose homeostasis as 
analysis of samples from subjects with type 2 diabetes revealed no overlap in gene expression 
profiles. We also showed the potential of TGS monitoring as a biomarker of disease trajectory, 
possibly enabling patient stratification for immunotherapy and monitoring of therapy outcomes. 
TGS measurement is simple, requires very small amounts of blood and integrates multiple 
aspects of Treg biology that would be difficult to quantify in individual assays.  
 Our biomarker discovery approach utilized a leave one out cross validation approach to 
identify algorithms with high AUCs, sensitivity and specificity for each comparison of interest 
with the resulting algorithms typically only including a subset of the 37 quantified transcripts. 
Comparisons between different algorithms revealed interesting trends in transcript utilization in 
samples of sorted Tregs versus PBMCs. For example, analysis of gene expression in sorted Tregs 
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revealed recurring cell surface receptors and cell signalling molecules, suggesting that T1D 
Tregs have intrinsic differences in their capability to interpret and transmit molecular signals. In 
contrast, evidence that one of the most differentially expressed gene in PBMC-based algorithms 
was FOXP3, suggests that these samples detect changes in Treg to Tconv ratios. This possibility 
is supported by the finding that FOXP3 was not present in algorithms derived from sorted Tregs; 
samples in which differential ratios between Treg to Tconv are eliminated. 
 Despite small sample sizes, we found that the TGS may be a novel approach to the long-
standing challenge of predicting and measuring T1D disease trajectory and intervention effects 
on the immunoregulatory balance. Specifically, application of a single TGS algorithm in two 
independent cohorts was able to identify the majority of new onset T1D subjects whose C-
peptide was likely to decline rapidly. Interestingly, pre-existing changes in Tregs seemed to 
correlate with future disease trajectory after ustekinumab treatment. These findings may indicate 
that a Treg-specific defect, instead of an immunoregulatory-imbalance, dictates future disease 
course. Our data also suggest possible differential ustekinumab-mediated intrinsic effects on 
Tregs and the immunoregulatory-balance in subjects with rapid versus slow C-peptide decline. 
Overall these data indicate that further testing of TGS-based algorithms in larger cohorts is 
warranted. 
To date, only two other studies have reported prognostic biomarkers after T1D onset. 
Hessner et al measured changes in PBMC gene expression upon culture in T1D plasma (17), 
finding that patients with higher inflammatory signature at baseline had slower C-peptide decline 
in response to IL-1RA in the AIDA trial (NCT00711503). Similarly, Linsley et al employed 
whole blood RNA-sequencing to find an increased T cell signature early after rituximab 
(NCT00279305) in patients with rapid C-peptide decline after 1 year (18). Compared to these 
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large "omic" based approaches, nanoString-based TGS measurement requires very few cells 
(<10,000) and minimal processing, making it easier to test in validation studies and more 
clinically feasible. As our understanding of T1D evolves from a linear to a relapsing-remitting 
autoimmunity model (19), it will be of interest to continue measuring the TGS prospectively 
over time, including before disease diagnosis, to determine if it may enable real-time evaluation 
of autoimmune activity.   
 In conclusion, these findings suggest that measuring Treg gene signatures could be a step 
towards a biomarker of immune status in T1D. Future application of our findings across multiple 
studies together with development of a cross-platform	and cross-chemistry standardization 
workflow may lead to the development of “universal” algorithms that could be applied to 
identify rapid vs slow progressors, monitor T1D over time, and/or select subjects likely to 





Sample collection and cell isolation. Peripheral blood from each cohort was obtained and 
cryopreserved as PBMCs (Supplemental Tables T1-5). Upon thawing, a proportion of each 
sample was used to isolate Tregs (sorted as CD4+CD25hiCD127lo cells, antibody information in 
supplemental Tables T6 & T7). Sorted Tregs and PBMCs were both lysed in RLT lysis buffer 
(Qiagen) at 3,500-5,000 cells/µL.   
 
nanoString analysis. mRNA expression was measured in 2µL Treg/PBMC lysates with a 
custom nCounter reporter probe set on nanoString nCounter FLEX or SPRINT systems. Sample 
quality was assessed by cartridge-specific normalization factors and positive control linearity. 
Gene expression data were normalized in four steps: 1) multiplication by sample’s normalization 
factor (geometric mean of positive controls divided by median); 2) total sum normalization 
equalling 5000 counts; 3) log2 transformation; and 4) ComBat batch correction (20). Each 
cohort, PBMCs or Tregs were batch-corrected separately.  
 
Statistics. Analyses were performed using R (21) and GraphPad Prism V8. Biomarker discovery 
analysis included 31 TGS genes (10) plus 6 genes differentially expressed between healthy and 
T1D. Differential expression was assessed using LiMMa (22) with p-value threshold of 0.1. 
Binary classifiers were built using logistic or elastic net regression (23), with a=0.65 (10) or 
=0.9. Where genotypes were available, the number of disease variant alleles (NDV) for each 
patient (either for a single SNP, or all eight SNPs tested) was included in the analysis as a 
covariate. Leave-one-out cross-validation was used to obtain performance estimates (area under 
the receiving operating characteristic curve (AUC), sensitivity, and specificity). For each 
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comparison, the best algorithm was selected on the basis of the highest AUC. To define 
sensitivity (true positive) and specificity (true negative), the definition of the cut-off for samples 
falling into one group versus another was set between 0.25 and 0.75 and is indicated by a dotted 
line on each biomarker score graph.  
 Comparison of two groups was performed by unpaired t-test (referenced in text, data not 
shown) and of multiple groups was performed by one-way ANOVA with Tukey’s multiple 
comparisons test (Figure 8C) and a p value of 0.05 was considered significant (data in 8C was 
not significantly different) using GraphPad Prism V8. 
 
Study approval. Protocols were approved by Clinical Research Ethics Boards of University of 
British Columbia, Benaroya Research Institute, and under the auspices of approved clinical trial 
protocols: UST1D (NCT02117765), START (NCT00515099 (24)) and T1DAL (NCT00965458 
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Figure 1. Altered intrinsic Treg gene signature in adults with T1D. CD25hiCD127lo Tregs were 
sorted from (A) adult new onset T1D (n=20) or (B) a cross-sectional T1D cohort (n=41) and age- 
and sex-matched controls (n=10 for A, or =37 for B). The Treg gene signature in the resulting 
lysates was measured on the nCounter FLEX platform. Biomarker scores and details (model of 
biomarker analysis selected [en, elastic net], number [n] of genes, AUC, sensitivity and 
specificity) for the best algorithm differentiating between T1D and healthy are indicated next to 
biomarker score dot-plots. Horizontal lines represent means with SD as error bars; dashed 





Figure 2. Addition of Treg-associated T1D SNPs enhances sensitivity of Treg-based 
algorithms. New algorithms were created using combinations of the gene signature data from 
sorted Tregs (cross sectional T1D and healthy cohorts) and a single indicated SNP genotype 
included as categorical value (i.e. each genotype given a specific weight) or as the number of 
disease variants/alleles (NDV) (i.e. 0, 1, or 2) encoding the indicated SNP. Shown are the best 
algorithms for each SNP: (A) genotype included as categorical value and (B-H) included as 
NDVs. (I) Biomarker score and algorithm for gene signature data combined with the average 
number of (Avg) disease variants for all SNPs assessed in A-H. Horizontal lines represent means 











Figure 3. Detection of an altered Treg gene signature in PBMCs from adults with T1D. The 
Treg gene signature was measured in PBMCs from (A) adult new onset T1D (n=19) or (B) a 
cross-sectional T1D cohort (n=36) and age- and sex-matched controls (n=10 for A, or =37 for 
B). Biomarker scores and details (as described in Figure 1; [p<0.1, cut-off for differential gene 
expression included in the biomarker discovery analysis; glm, generalized linear model]) for the 
best algorithm differentiating between T1D and healthy are indicated next to biomarker score 
dot-plots. Horizontal lines represent means with SD as error bars; dashed horizontal lines 




Figure 4. Addition of Treg-associated T1D SNPs enhances sensitivity of PBMC-based 
algorithms. New algorithms were created using combinations of gene signature data from 
PBMCs (isolated from cross sectional T1D and healthy cohorts) and a single indicated SNP 
genotype included as categorical value (i.e. each genotype given a specific weight) or as the 
number of disease variants/alleles (NDV) (i.e. 0, 1, or 2). (A&B) genotype included as 
categorical value and (C-H) genotype included as NDVs. (I) Biomarker scores and algorithm 
details combining gene signature data and the average number of (Avg) disease variants across 
all SNPs assessed. Horizontal lines represent means with SD as error bars; dashed horizontal 
lines represent cut-offs for sensitivity and specificity calculations. 
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Figure 5. Differential gene usage in Treg versus PBMC-derived algorithms. Summary of 
which genes were present in the best performing algorithms from the cross-sectional T1D and 
healthy cohorts. (A) Treg-based algorithms described in Figure 1B and 2. (B) PBMC-based 
algorithms described in Figure 3B and 4. Each of the 37 mRNAs measured is listed, grey and 





Figure 6. Altered Treg gene signature in type 2 diabetes (T2D) compared to T1D and healthy 
controls. The Treg gene signature was measured in sorted CD25hiCD127lo Tregs and PBMCs 
from the indicated age- and sex-matched cohorts using the nCounter SPRINT system. For Tregs: 
T2D n=29, T1D n=7, and healthy controls (HC) n=9. For PBMCs: T2D n=33, T1D n=10, and 
healthy controls n=9. Shown is a principal component analysis representing expression of all 37 




Figure 7. Treg gene signature algorithms differentiate type 1 or type 2 diabetes, and healthy 
controls. PBMC and Treg lysates from the indicated T1D or type 2 diabetes (T2D) cohorts were 
run on a nCounter SPRINT system together with age- and sex-matched healthy control samples. 
(A) Biomarker scores and performance when the algorithm from Figure 1B was applied to T1D 
and healthy control (HC) Treg data. (B&C) Biomarker scores and details (as described in Figure 
1) of the best biomarker algorithm differentiating between Tregs from (B) T1D or (C) healthy 
controls and T2D samples. (D) Biomarker scores and performance when the algorithm from 
Figure 3B was applied to T1D and healthy control PBMC data. (E&F) Biomarker scores and 
details (as described in Figure 1&3) of the best biomarker algorithm differentiating between (E) 
T1D or (F) control and T2D samples in PBMCs. Horizontal lines represent means with SD as 
error bars; dashed horizontal lines represent cut-offs for sensitivity and specificity calculations. 
(G&H) Summary of gene usage in each (G) Treg or (H) PBMC-based algorithm described in A-
F. Each of the 37 mRNAs measured is listed, grey and white squares indicate genes which were 






Figure 8. The Treg gene signature as a predictive biomarker of C-peptide decline. (A) C-
peptide was quantified (2h AUC MMTT) in new onset T1D patients in the placebo arms of the 
T1DAL and START clinical trials (see CONSORT Flow Diagrams in Supplemental Figures 
S1&2) at baseline (M0), 6 months (M6) and 24 months (M24). The absolute change in C-peptide 
from M0 to M24 was calculated and subjects were divided into those with slow (n=9), moderate 
(n=8) or rapid (n=7) decline based on terciles. (B&C). Tregs (CD4+CD25hiCD127lo) were sorted 
from cryopreserved PBMCs isolated from these subjects at baseline (M0) and the TGS was 
measured. (B) Biomarker score and details (as described in Figure 1&3) of the best algorithm 
predicting future rapid, slow, or moderate C-peptide decline. Horizontal lines represent means 
with SD as error bars; dashed horizontal lines represent cut-offs for sensitivity and specificity 
calculations. (C) Expression of the indicated genes plotted by rate of C-peptide decline group, 
with one-way ANOVA with Tukey’s multiple comparisons test (* p-value £0.05, but data not 




Figure 9. The Treg gene signature as a predictive biomarker of C-peptide decline in T1D 
subjects treated with ustekinumab. Adult new onset T1D patients were treated with 
ustekinumab as outlined in the CONSORT Flow diagram in Supplemental Figure S3. (A) C-
peptide was quantified (2h AUC MMTT) at baseline (M0), 1 month (M1) and 12 months (M12), 
and absolute change in C-peptide from M0 to M12 was calculated. Subjects were divided into 
those with slow (n=11) or rapid (n=5) decline based on the absolute decline at M12, with slow 
subjects defined as those who lost less than 0.3pmol of C-peptide/year. (B-E) The TGS was 
measured in sorted CD25hiCD127lo Tregs or PBMCs from M0 and M9 samples. (B) Test details 
when the algorithm from Figure 8B was applied to M0 Treg data. (C) Treg-based algorithm and 
biomarker scores for slow versus rapid C-peptide decline using relative TGS data (M9/M0 prior 
to log2 transformation). (D) Treg- and (E) PBMC-based algorithm and biomarker scores using 
M9 TGS expression data. Horizontal lines in (C-E) represent means with SD as error bars; 
dashed horizontal lines represent cut-offs for sensitivity and specificity calculations. (F) 
Summary of gene usage in c-peptide decline algorithms described in B-E.  
